Health
South Eastern Sydney
Local Health District

# **ClinTrial Refer** – a Mobile App for IOS and android platforms to connect patients and haematologists with local clinical research trials.


**Roslyn Ristuccia (St George/ Sutherland Hospitals)**
**Admir Huseincehajic (Concord Repatriation General Hospital)**
**Haematology Clinical Research Unit Managers**

**Judith Trotman (Concord Repatriation General Hospital)**
**Xavier Badoux (St George/ Sutherland Hospitals)**
**Haematologists**

**On behalf of the Haematology Clinical Research Network, NSW/ACT**

# Introduction

- There are significant challenges recruiting patients to haematology trials:

  Rarity and low incidence of blood disease

  Geographical Challenges
  Cost- can't run all studies at all site
  Knowledge Management- what trials and where?

- Patient referral between sites gives patients all treatment options available.

# Introduction

- NSW Haematology Network of clinical trials co-ordinator staff founded in 2006
  - Decided to develop an App to facilitate referrals, and together with Haematologists, developed specifications for ClinTrial Refer
    Launched in May
    Available to download from iTunes and Google Play for free
    Easy to use

In the fast moving world of exciting new targeted therapies for blood cancers in particular, **ClinTrial Refer** helps Haematologists find an appropriate trial for their patients with an easy to navigate list across a broad spectrum of haematological malignancies.

User can narrow down the search by Disease, Location, Trial Status and Sponsor.



Navigate through a broad spectrum of Haematological malignancies



Select Location of interest, usually closest to patients home



For example, if your patient has Diffuse Large B-Cell Lymphoma, you can select the Disease and search all available trials for DLBCL



Click “Search” button and you should see all currently recruiting DLBCL trials



If a patient with DLBCL is interested in participating in the ALLG REMARC study...



On **ClinTrial Refer** the clinician can view Inclusion...



# … and Exclusion Criteria to screen the patient for eligibility



… then can identify which hospitals in NSW can offer the study.



They can contact the responsible person for more details and/or possible enrolment, including emailing them directly using the email icon in the top right



To learn more about the study,
the ANZ Clinical Trials Registry Trial Registration Number (TRN) can be copied



… and pasted directly on to the ANZ Clinical Trial Registry website



… and all details can be viewed…


## Trial from ANZCTR

| | |
|---|---|
| **Trial ID** | ACTRN12611000085976 |
| **Trial Status:** | Registered |
| **Date Submitted:** | 23/12/2010 |
| **Date Registered:** | 24/01/2011 |
| | **Prospectively registered** |

**Page 1**

| | |
|---|---|
| **Public title** | Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) |
| **Study title in 'Participant-Intervention-Comparator- Outcome (PICO)' format** | Double blind randomized phase III study of Lenalidomide (Revlimid Registered Trademark) maintenance versus Placebo in responding elderly patients with diffuse large B cell lymphoma (DLBCL) and treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in first line |
| **Secondary ID [1]** | Clinical trials.gov NCT01122472 |
| UTN | |
| Trial acronym | REMARC |

**Page 2**

| **Health condition(s) or problem(s) studied:** | |
|---|---|
| Diffuse large B cell lymphoma (DLBCL) in elderly patients | |
| **Condition category:** | **Condition code:** |
| Cancer | Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma |

**Page 3**

| | |
|---|---|
| **Descriptions of intervention(s) / exposure** | 25mg daily lenalidomide for 21 days of a 28 day cycle of maintenance therapy for up to 26 cycles. Lenalidomide is an oral tablet. |
| **Intervention Code:** | Treatment: drugs |
| **Comparator / control treatment** | placebo oral tablet contains the excipients used for the drug product without the active ingredient and it conforms to the colour and size for blinded study. It is taken daily for 21 days of a 28 day cycle of maintenance therapy for up to 26 cycles. |
| **Control group** | Placebo |

**Page 4**

| | |
|---|---|
| **Primary Outcome:** | to determine the benefit estimated by the progression-free survival associated with lenalidomide maintenance compared to placebo in responding patients treated with R-CHOP for diffuse large B-cell lymphoma. Progression will be measured by tests such as CT scan, PET scan and Bone Marrow examination. |
| *Timepoint:* | 3 years after the last patient is randomised or the first date of disease progression or relapse |

# Outcome Referrals- a 300% increase in referrals since the App launch in May



# Snapshot of usage - Sep 2013 - user engagement- 91% of NSW users are repeat users



# ClinTrial Refer consumer groups

You are here: Home ▸ ClinTrial Refer

## ClinTrial Refer

**Lymphoma Australia, CEO Sharon Millman recently attended the launch of a new free app titled Clin Trials Refer** at Concord Hospital. Clin Trials Refer supplies a current listing of active and pending haematology clinical research trials in NSW and ACT. The app will be updated monthly, with trial location sites, and contact details for the trial you are interested in knowing more about.

Lymphoma Australia has found from speaking with many patients that the process of finding a Lymphoma trial relevant to your subtype can be a very confusing and time consuming process. According to Lymphoma Australia CEO, Sharon Millman, this app is simple to use and the information can be easily discussed with your treating doctor.

**Clin Trials Refer is the result of the tireless work of the development team at the Haematology Clinical Research Network NSW. (Read more from the Media Release HERE)**

*ClinTrial Refer Launch with Lymphoma Australia*

*New App on IPhone and IPad*

**Now Available from the App Store (Click Here) Screenshots of the app Below.**






Lymphoma Australia website advises its consumers to use the App.

# Lessons learned

- Patients will travel to other sites for life-lengthening treatments
- Haematologists will refer to other sites
- That a strong networked partnership between haematologists, research co-ordinators and participants can enable patients to access best available treatments over the state
- That innovation can help partnerships

Currently the App is specific for Haematology in NSW and the ACT but can be adopted to any clinical research portfolio both in Australia and internationally


Haematology
NSW